All Approved Indications Of Five Akeso's Innovative Drugs Included In China's Latest NRDL: Featuring Two First-In-Class Bispecifics With New First-Line Indications And Three Newly Negotiated Drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback